|Articles|August 26, 2022
Choose Eurofins’ new state-of-the-art aseptic sterile fill/finish for clinical supplies
Author(s)Eurofins
Industry changes can often introduce additional risks to the sterile fill/finish process, resulting in production delays, additional costs, and safety concerns. Choose Eurofins BioPharma Product Testing to help eliminate associated risks.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Launch in Lockstep: Biopharma Readiness for the CNPV’s Accelerated Clock
2
How Miniaturized Analytics Are Transforming Aseptic Bioprocessing Control
3
Industry Experts Probe CNPV Impacts
4
CDC’s Policy Shift on Autism and Vaccines Spurs Biopharma Quality/System Concerns
5
